10 Sep 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Dr Marschall S Runge is elected as a member of the board of directors of Eli Lilly, effective September 1, 2013. Dr Runge, 59, is the executive dean for the School of Medicine at the University of North Carolina at Chapel Hill (UNC), US.
As a member of Lilly's board, Dr Runge will serve on the Science and Technology Committee and the Public Policy and Compliance Committee.
"I am very pleased to welcome Marschall Runge to the Lilly board," said Dr John Lechleiter, Eli Lilly's chairman, president and chief executive officer. "Dr Runge brings to the Lilly board a broad background in healthcare, with extensive experience as a practicing physician, clinical researcher, and dean of a major academic medical institution."
Dr Lechleiter added, "His appreciation of the importance of scientific research, coupled with his first-hand experience in patient care, will help Lilly deliver on its commitment to discover and develop innovative medicines that make a difference for patients in need."
In his role as executive dean of the UNC School of Medicine, Dr Runge provides overall academic and clinical leadership for the School of Medicine and the UNC Health Care System. In addition to being the chair of the Department of Medicine, Dr Runge is also principal investigator and director of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute at UNC-Chapel Hill, where he has financial, human resource and strategic oversight responsibilities for the program.
The NC TraCS Institute is one of 60 medical research institutions working together as part of a national consortium to improve the way biomedical research is conducted across the country and to reduce the time it takes for laboratory discoveries to become new treatments for patients.